Sartel: Advanced Angiotensin II Receptor Blocker Therapy
| Product dosage: 40mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.50 | $75.02 (0%) | 🛒 Add to cart |
| 60 | $2.00 | $150.04 $120.03 (20%) | 🛒 Add to cart |
| 90 | $1.50 | $225.06 $135.03 (40%) | 🛒 Add to cart |
| 120 | $1.30 | $300.07 $156.04 (48%) | 🛒 Add to cart |
| 180 | $1.10 | $450.11 $198.05 (56%) | 🛒 Add to cart |
| 270 | $1.00 | $675.17 $270.07 (60%) | 🛒 Add to cart |
| 360 | $0.80
Best per pill | $900.22 $288.07 (68%) | 🛒 Add to cart |
Sartel is a prescription medication belonging to the class of angiotensin II receptor blockers (ARBs), specifically containing the active ingredient Telmisartan. It is designed for the management of hypertension, offering precise blood pressure control and cardiovascular risk reduction. Clinically proven, Sartel works by selectively blocking the binding of angiotensin II to the AT1 receptor, resulting in vasodilation and decreased aldosterone secretion. This mechanism provides sustained 24-hour efficacy with a single daily dose, supporting long-term therapeutic goals in hypertensive patients. Its favorable pharmacokinetic profile includes a long half-life and minimal fluctuation in plasma concentration, ensuring consistent antihypertensive action.
Features
- Contains Telmisartan as the active pharmaceutical ingredient
- Available in multiple strengths: 20 mg, 40 mg, and 80 mg tablets
- Once-daily dosing regimen for improved adherence
- High bioavailability and selective AT1 receptor blockade
- Long elimination half-life (approximately 24 hours)
- Minimal metabolism via cytochrome P450 system
- Not significantly affected by food intake
- Film-coated tablets for ease of swallowing
Benefits
- Provides effective and sustained reduction in systolic and diastolic blood pressure
- Lowers the risk of cardiovascular events such as stroke and myocardial infarction in high-risk patients
- Offers renal protective effects, particularly in patients with type 2 diabetes and overt nephropathy
- Demonstrates a favorable side effect profile with low incidence of cough compared to ACE inhibitors
- Supports patient compliance through convenient once-daily dosing
- Exhibits potential metabolic benefits, including improvement in insulin sensitivity
Common use
Sartel (Telmisartan) is primarily indicated for the treatment of essential hypertension in adults. It may be used as monotherapy or in combination with other antihypertensive agents, such as thiazide diuretics or calcium channel blockers, to achieve blood pressure targets. Additionally, it is employed for cardiovascular risk reduction in patients unable to tolerate ACE inhibitors, and in the management of diabetic nephropathy in hypertensive patients with type 2 diabetes mellitus and elevated serum creatinine levels or proteinuria.
Dosage and direction
The recommended initial dose of Sartel is 40 mg once daily. Dosage may be increased to 80 mg once daily based on blood pressure response. In some patients, a dose of 20 mg may be considered, particularly those with hepatic impairment or volume depletion. Sartel may be administered with or without food. Tablets should be swallowed whole with a glass of water; they should not be crushed or chewed. Regular monitoring of blood pressure is advised to determine the full effect of the dose, which may take up to 4 weeks. Dose adjustment is not typically necessary in elderly patients or those with renal impairment, though caution is advised in severe renal dysfunction.
Precautions
Patients should be advised to avoid pregnancy while taking Sartel due to the risk of fetal harm. Use with caution in patients with renal artery stenosis, as there is a potential risk of renal impairment. Volume-depleted patients (e.g., those on high-dose diuretics) should be monitored for symptomatic hypotension. Hepatic impairment may require dose adjustment; avoid use in severe hepatic dysfunction. Regular monitoring of renal function and electrolytes (particularly potassium) is recommended, especially when used concomitantly with other agents affecting the renin-angiotensin system. Patients should be informed about the possibility of dizziness or lightheadedness, particularly during initial therapy.
Contraindications
Sartel is contraindicated in patients with known hypersensitivity to Telmisartan or any component of the formulation. It must not be used during pregnancy, especially in the second and third trimesters, due to the risk of causing injury or death to the developing fetus. Concomitant use with aliskiren in patients with diabetes or renal impairment (GFR <60 mL/min/1.73 m²) is contraindicated. Avoid use in patients with severe hepatic impairment (Child-Pugh class C).
Possible side effect
Common adverse reactions include dizziness, upper respiratory tract infection, back pain, sinusitis, and diarrhea. Less frequently, patients may experience hypotension, hyperkalemia, increased serum creatinine, angioedema (though rare compared to ACE inhibitors), headache, fatigue, and abdominal pain. In clinical trials, the incidence of cough was similar to placebo. Serious but rare side effects include renal dysfunction, orthostatic hypotension, and anaphylactoid reactions. Patients should report any signs of infection, unexplained muscle pain, or symptoms of high potassium levels such as muscle weakness or irregular heartbeat.
Drug interaction
Concomitant use with other antihypertensive agents may potentiate blood pressure-lowering effects. NSAIDs may reduce the antihypertensive efficacy and increase the risk of renal impairment. Potassium-sparing diuretics, potassium supplements, or salt substitutes containing potassium may increase the risk of hyperkalemia. Lithium levels may increase when co-administered with Sartel, requiring monitoring. Use with ACE inhibitors or aliskiren is not recommended due to increased risk of adverse events such as hyperkalemia, hypotension, and renal dysfunction. Telmisartan may increase the concentration of digoxin; monitoring is advised.
Missed dose
If a dose of Sartel is missed, it should be taken as soon as remembered on the same day. If it is nearly time for the next dose, the missed dose should be skipped, and the regular dosing schedule resumed. Patients should not take a double dose to make up for a missed one. Consistency in dosing is important for maintaining stable blood pressure control; setting a daily reminder may help avoid missed doses.
Overdose
Overdose of Sartel may manifest as hypotension, tachycardia, or bradycardia, and dizziness. Bradycardia could also occur due to vagal stimulation. In case of suspected overdose, supportive measures should be instituted, including close monitoring of vital signs and electrolyte levels. Management primarily consists of intravenous normal saline to correct hypotension and, if necessary, vasopressors. Telmisartan is not significantly dialyzable due to high protein binding, so hemodialysis is not expected to be effective. Symptomatic and supportive treatment in a clinical setting is recommended.
Storage
Store Sartel tablets at room temperature, between 15°C and 30°C (59°F and 86°F), in a dry place protected from light and moisture. Keep the container tightly closed and out of reach of children and pets. Do not use beyond the expiration date printed on the packaging. Proper storage ensures stability and efficacy of the medication; avoid storing in bathrooms or near sinks where humidity levels are high.
Disclaimer
This information is intended for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting or changing any medication regimen. Individual patient responses may vary, and the prescribing physician should determine the appropriate therapy based on the patient’s specific medical condition, history, and concurrent medications. Do not disregard or delay seeking medical advice due to content provided here.
Reviews
Clinical studies and post-marketing surveillance indicate that Sartel (Telmisartan) is well-tolerated and effective in the majority of hypertensive patients. In randomized controlled trials, it demonstrated non-inferiority to other ARBs and ACE inhibitors, with a notably low incidence of cough. Many physicians appreciate its metabolic neutrality and once-daily convenience, which supports long-term adherence. Patient reviews often highlight reliable blood pressure control and minimal side effects, though individual experiences may vary. Overall, it is regarded as a valuable option in antihypertensive therapy, particularly for those requiring renal or cardiovascular protection.